冠脉舒对冠心病患者血浆组织型纤溶酶原激活物及其抑制物的影响

Effects of Guan-Mai-Shu on Tissue-Type Plasminogen Activator and Plasminogen Activator Inhibitor in the Plasma of Patients with Coronary Heart Disease

免费下载全文查看/发表评论下载PDF阅读器

DOI：

中文关键词: 冠脉舒冠心病组织型纤溶酶原激活物纤溶酶原激活物抑制物

英文关键词:Guan-Mai-Shu coronary heart disease tissue-type plasminogen activator plasminogen activator inhibitor

基金项目:

作者	单位
熊小忠	湖南医科大学附属第二医院心血管内科长沙 410011
莫树松	湖南医科大学附属第二医院心血管内科长沙 410011
祁述善	湖南医科大学附属第二医院心血管内科长沙 410011
王钟林	湖南医科大学附属第二医院心血管内科长沙 410011

摘要点击次数: 1479

全文下载次数: 999

中文摘要:

本课题研究中药冠脉舒对冠心病患者血浆组织型纤溶酶原激活物(t·PA)及其抑制物(PAI)的影响。将50例患者随机分为治疗组(30例)和对照组(20例),并与健康人对照。结果表明,同健康人比较,冠心病患者血浆t-PA活性明显降低(P<0.05),PAI活性明显升高(P<0.01)。经冠脉舒治疗后,t-PA活性升高(P<0.001),PAI活性降低(P<0.001)。提示冠脉舒能提高冠心病患者血浆纤溶活性。

英文摘要:

Effects of Guan-Mai-Shu (GMS), a traditional Chinese medicine preparation, on tissue-typeplasminogen activator (t-PA) and plasminogen activator inhibitor (PAI) in the plasma of patientswith coronary heart disease were studied. It was found that those patients had a significant decreasein t-PA activity (P< 0.05) and a significant increase in PAI activity (P< 0.01) compared to healthysubjects. After treatment of GMS, t-PA activity significantly increased (P< 0.001), while PAIactivity decreased (P< 0.001). These results indicated that GMS could raise t-PA activity and reducePAI activity in the plasma of patients with coronary heart disease.

关闭